Koedoot C G, de Haan R J, Stiggelbout A M, Stalmeier P F M, de Graeff A, Bakker P J M, de Haes J C J M
Department of Medical Psychology, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands.
Br J Cancer. 2003 Dec 15;89(12):2219-26. doi: 10.1038/sj.bjc.6601445.
In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients' values and preferences become important issues. Patients, however, may have a treatment preference before they even meet their medical oncologist. An insight into the patient's decision-making process can support clinicians having to inform their patients. Patients (n=207) with metastatic cancer, aged 18 years or older, able to speak Dutch, for whom palliative chemotherapy was a treatment option, were eligible for the study. We assessed the following before they consulted their medical oncologist: (1) socio-demographic characteristics, (2) disease-related variables, (3) quality-of-life indices, (4) attitudes and (5) preferences for treatment, information and participation in decision-making. The actual treatment decision, assessed after it had been made, was the main study outcome. Of 207 eligible patients, 140 patients (68%) participated in the study. At baseline, 68% preferred to undergo chemotherapy rather than wait watchfully. Eventually, 78% chose chemotherapy. Treatment preference (odds ratio (OR)=10.3, confidence interval (CI) 2.8-38.0) and a deferring style of decision-making (OR=4.9, CI 1.4-17.2) best predicted the actual treatment choice. Treatment preference (total explained variance=38.2%) was predicted, in turn, by patients' striving for length of life (29.5%), less striving for quality of life (6.1%) and experienced control over the cause of disease (2.6%). Patients' actual treatment choice was most strongly predicted by their preconsultation treatment preference. Since treatment preference is positively explained by striving for length of life, and negatively by striving for quality of life, it is questionable whether the purpose of palliative treatment is made clear. This, paradoxically, emphasises the need for further attention to the process of information giving and shared decision-making.
在姑息性癌症治疗中,选择姑息化疗还是最佳支持治疗可能会很困难。在决策过程中,提供信息以及患者的价值观和偏好成为重要问题。然而,患者甚至在见到肿瘤内科医生之前可能就已经有了治疗偏好。深入了解患者的决策过程有助于指导临床医生告知患者相关信息。年龄在18岁及以上、会说荷兰语、转移性癌症患者且姑息化疗为一种治疗选择的患者(n = 207)符合本研究条件。在他们咨询肿瘤内科医生之前,我们评估了以下内容:(1)社会人口学特征,(2)疾病相关变量,(3)生活质量指标,(4)态度以及(5)对治疗、信息和参与决策的偏好。在做出实际治疗决策后进行评估,这是主要研究结果。207名符合条件的患者中,140名患者(68%)参与了研究。基线时,68%的患者更倾向于接受化疗而非静观其变。最终,78%的患者选择了化疗。治疗偏好(优势比(OR)= 10.3,置信区间(CI)2.8 - 38.0)和延迟决策方式(OR = 4.9,CI 1.4 - 17.2)最能预测实际治疗选择。反过来,治疗偏好(总解释方差 = 38.2%)由患者对生命长度的追求(29.5%)、对生活质量追求较少(6.1%)以及对病因的掌控感(2.6%)所预测。患者的实际治疗选择最强烈地由其咨询前的治疗偏好所预测。由于治疗偏好由对生命长度的追求正向解释,由对生活质量的追求负向解释,所以姑息治疗的目的是否明确值得怀疑。矛盾的是,这强调了需要进一步关注信息提供和共同决策的过程。